← Markets

Janux Therapeutics, Inc.

JANX · NASDAQ

Market closed$16.26$0.420000 (+2.65%)After hours $16.06 · -1.23%

Key statistics

Previous close$15.84
Open$15.68
Day high$16.38
Day low$15.65
52-week high$35.34
52-week low$12.12
Market cap991.61M
Volume775.16K
Average volume1.12M
P/E ratio-8.84
Forward P/E—
EPS-1.84
Dividend yield0.00%

Market context

Why it moved

JANX shares are trading higher, buoyed by continued positive sentiment following the company's previously announced strong updated clinical data for its dual clinical programs, which had driven significant investor interest in Janux Therapeutics.

InstagramMoomooArchiveofourownWeatherFacebook

What is happening

Recent company-specific developments and publisher coverage.

July 16, 2026Janux Therapeutics closed up modestly, gaining around 1.6%, as the broader healthcare sector offered a constructive backdrop with UBS upgrading its outlook on biopharma and biotechnology stocks, citing improving fundamentals, stabilizing regulatory conditions, and anticipated M&A activity. The most notable company-specific development remains the April discontinuation of JANX008 to concentrate resources on its remaining oncology pipeline, including JANX014 for prostate cancer, which dosed its first participant earlier that month. In after-hours trading, shares are essentially flat, slightly pulling back from the day's close.

1.5843

July 14, 2026Janux Therapeutics closed modestly lower, slipping alongside a broader healthcare sector pullback as macro headwinds weighed on risk assets. U.S.-Iran tensions sent oil prices surging and rattled equity markets, with the S&P 500 declining and the healthcare ETF (XLV) also edging lower. For Janux specifically, the stock continues to trade near multi-month lows following April's discontinuation of its JANX008 cancer program and a subsequent analyst price target cut by JonesTrading from $50 to $28 (maintaining Buy). A routine CEO option exercise reported July 8 offered no new strategic signal. The broader biotech backdrop remains constructive — Goldman Sachs cited strong M&A appetite in oncology and immunology — but Janux faces near-term pipeline scrutiny as investors await progress on JANX014, its prostate cancer candidate that recently dosed its first participant.

-1.5854

July 11, 2026Janux Therapeutics declined amid a broader biotech sector that has been outperforming, as company-specific headwinds drew investor focus. The stock's late-June removal from multiple Russell growth indexes — including the Russell 2000, 2500, and 3000 Growth benchmarks — continues to weigh on sentiment, with forced selling from index-tracking funds potentially compressing liquidity just as the company navigates discontinuation of JANX008 and a CMO transition. Analysts highlight that near-term catalysts remain clinical: data from JANX007 and JANX014 and progress on the Bristol Myers Squibb partnership toward an IND filing. CEO David Campbell exercised 7,000 options at $4.21, a sign of insider confidence, though continuing losses and prior C-suite turnover keep execution risk elevated.

-2.0896

July 10, 2026Janux Therapeutics edged up modestly in regular trading before pulling back in after-hours, slipping roughly 2%, as investors digest the company's late-June removal from multiple Russell growth indexes — including the Russell 2000, 2500, 3000, and Small Cap Composite Growth benchmarks — which could prompt index-tracking fund rebalancing and shift the stock's investor base. The headline driving the narrative remains its clinical-stage TRACTr platform and Bristol Myers Squibb partnership, with near-term catalysts hinging on JANX007 and JANX014 trial readouts, while the index exit adds volatility risk around those events. The broader biotech sector has been highlighted as a market leader amid M&A speculation, which provides a constructive backdrop even as ongoing losses and CMO transition keep execution risk elevated.

0.5402

July 9, 2026Janux Therapeutics closed up over 3% on above-average volume, outperforming the broader market amid a risk-off session driven by renewed U.S.-Iran tensions and surging oil prices. The gain stands out given the healthcare sector's continued rotation into favor — XLV has surged roughly 6.6% in June alone and healthcare stocks are reportedly showing their strongest relative strength in over 15 years. Biotech sentiment has been broadly elevated, with CNBC's Jim Cramer calling biotech 'the hottest group in the market' and predicting an M&A wave as the regulatory environment under new FDA leadership becomes more deal-friendly — a tailwind that could benefit clinical-stage names like Janux.

3.1579

July 6, 2026Janux Therapeutics closed modestly lower, edging down as the broader healthcare sector faced headwinds despite a tech-led rally on Wall Street. The XLV healthcare ETF declined on the session amid sector-wide pressure, with major names like Johnson & Johnson, AbbVie, and Pfizer all posting notable losses. For Janux specifically, investor sentiment remains cautious following the April 2026 discontinuation of its JANX008 cancer program, with the company refocusing resources on its remaining pipeline—including JANX014, a prostate cancer candidate that recently dosed its first participant. In after-hours trading, JANX rebounded, rising over 1%, outpacing the XLV ETF's modest after-hours gain of 0.53%, as investors continue to monitor pipeline progress and Fed policy signals heading into Q2 earnings season.

-0.8366

July 3, 2026Janux Therapeutics surged 6%, outperforming broader healthcare peers as the XLV sector ETF closed near 52-week highs amid a healthcare-led rally on Wall Street. The move comes amid a backdrop of mixed analyst sentiment — Truist initiated coverage with a Buy and $26 price target on June 25 while acknowledging tolerability challenges for lead candidate JANX007, and RBC maintains an Outperform with a $30 target — though headwinds linger from the recent CMO departure and removal from multiple Russell growth benchmarks in late June.

6.0027

July 2, 2026Janux Therapeutics fell nearly 5% on the first trading day of July, weighed down by a cluster of headwinds including its removal from multiple Russell growth benchmarks (Russell 2000, 2500, 3000, and Small Cap Comp) effective late June — a development that can trigger forced selling from index-tracking funds. The index exclusions follow a difficult stretch that includes the June 23 departure of Chief Medical Officer William Go and a Barclays downgrade to Underweight in April. Despite a Truist Securities Buy initiation on June 25 with a $26 target and bullish analyst consensus (avg. target ~$37), investor sentiment remains cautious as the company narrows its pipeline focus around its TRACTr platform candidates.

-4.5573

Business Wire · May 7, 2026Janux Therapeutics Reports First Quarter 2026 Financial Results and Business HighlightsSeeking Alpha · May 4, 2026Janux Therapeutics: Strong Buy As Pipeline Advances, Stock Trades Below Cash ValueStocktwits · April 27, 2026JANX Stock Edges Up After Hours After Discontinuing Cancer Program In Favor Of Remaining PipelineClinical Trials Arena · April 17, 2026First patient receives JANX014 dose in Janux’s trial for mCRPCInvesting.com · January 26, 2026Janux Therapeutics appoints William Go as new chief medical officerPharmaceutical Technology · January 22, 2026BMS bets on Janux’s novel solid tumour therapy through $850m dealPharmaceutical Executive · January 22, 2026Janux Therapeutics Enters $850 Million Collaboration and Exclusive License Agreement with Bristol Myers Squibb to Develop Tumor-Activated TherapeuticsBioPharma Dive · January 22, 2026Bristol Myers buys into Janux’s ‘masked’ T cell engagers
Benzinga · June 25, 2026Truist Securities Assumes Janux Therapeutics at Buy, Lowers Price Target of $26
Mt Newswire · May 8, 2026RBC Raises Janux Therapeutics Price Target to $30 From $27, Keeps Outperform Rating
Benzinga · May 8, 2026Piper Sandler Maintains Overweight on Janux Therapeutics, Lowers Price Target to $26
Benzinga · May 8, 2026Wedbush Maintains Outperform on Janux Therapeutics, Lowers Price Target to $36
Mt Newswire · May 8, 2026Wedbush Adjusts Janux Therapeutics Price Target to $36 From $45, Maintains Outperform Rating
Benzinga · May 8, 2026Guggenheim Maintains Buy on Janux Therapeutics, Lowers Price Target to $58
Mt Newswire · May 7, 2026Earnings Flash (JANX) Janux Therapeutics, Inc. Reports Q1 Revenue $3.7M, vs. FactSet Est of $4.4M
Benzinga · April 28, 2026Jones Trading Maintains Buy on Janux Therapeutics, Lowers Price Target to $28

Peers

S&P 500SPX · $7,457.69-1.01%Beam Therapeutics Inc.BEAM · $27.53-3.03%Relay Therapeutics, Inc.RLAY · $19.91+2.79%Genmab A/SGMAB · $28.72-0.90%Xencor, Inc.XNCR · $17.47+16.86%CytomX Therapeutics, Inc.CTMX · $3.62-1.23%Adecoagro S.A.AGRO · $10.07+1.41%Celldex Therapeutics, Inc.CLDX · $35.35-0.14%Vera Therapeutics, Inc.VERA · $38.50-1.58%Biohaven Ltd.BHVN · $15.44+8.96%Travere Therapeutics, Inc.TVTX · $56.71+2.59%Adagene Inc.ADAG · $3.59+0.28%